Merck’s exceptional revenue growth in 2021 and the first half of 2022 came thanks to three big brands, one of which is not even approved by the FDA yet.

On Friday, Merck announced positive results on its patent infringement case against Viatris, while Amgen faces political headwinds from the White House.

​​​​​​​The FDA will still allow continued distribution of sitagliptin containing NTTP with an acceptable intake limit of 37 ng per day and up to 246.7 ng per day.